tirzepatide trial obesity without diabetes surmount-1 weight loss non-diabetic For the first time, and semaglutide were put in Lilly Decides to Advance Tirzepatide

Peer-review model: Single blind Peer-review started: October 17, 2023 First decision: October 31, 2023 Article in press: December 2, 2023 Specialty type: Gastroenterology and hepatology Country/Territory of origin: Australia Peer-review reports scientific quality classification Grade A (Excellent): A Grade B (Very good): B Grade C (Good): C Grade D (Fair): 0 Grade E (Poor): 0 P-Reviewer: Barone M, Italy

Mahmoud NN, Hamad K, Al Shibitini A, Juma S, Sharifi S, Gould L, Mahmoudi M

Su mecanismo de accin, adems de favorecer el control glucmico, induce a una disminucin del apetito, un aumento de la sensacin de saciedad y una reduccin del exceso de grasa, incluida la grasa visceral en el permetro de la cintura 4

FDA approves Ozempic for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease, updates Rybelsus label [Press release], Novo Nordisk (2020) Rapid weight loss can increase the risk of acute kidney injury in wrestlers, BMJ Open Sport & Exercise Medicine (2023) Acute kidney injury associated with semaglutide, Kidney Medicine (2021) Ozempic label, Novo Nordisk (2023) Can glucagon-like peptide-1 receptor agonists cause acute kidney injury